Adoptive Cell Transfer in General
The basic concept of ACT is to identify cancer-reactive lymphocytes, harvest those from a cancer patient, stimulate them ex vivo, expand the antitumor lymphocytes ex vivo and reintroduce them into the patient in order to enhance the antitumor effect of the cells [1, 2] . Peripheral blood, tumor biopsies, malignant effusions and resected lymph nodes are the sources for T cells used for autologous ACT. The use of antigen-specific CD8+ cytotoxic T cells (CTLs) derived from peripheral blood lymphocytes is a widely clinically tested method in ACT for cancer [1, 2] .
The application of tumor-infiltrating lymphocytes (TILs) isolated from fresh tumor biopsies appears promising when reinfused into the patient after lymphoablative chemotherapy [3, 4] . Especially the TIL strategy is a technical challenge and labor-and time-intensive. T-cell counts strongly vary in the different biopsies that are taken, and only one third contains enough T cells to proceed with ex vivo activation and expansion. The full process until reinfusion takes about 6 weeks and needs stimulation cultures with OKT3 (anti-human CD3 monoclonal antibody), irradiated allogeneic feeder peripheral blood mononuclear cells and IL-2 [5] .
A further development of ACT is the use of engineered T cells. Those could be the source of choice if the number of TILs in a biopsy is too low to perform TIL infusion or if the tumor is poorly antigenic. T cells are engineered to express tumor antigen-specific receptors; alternatively chimeric tumor antigen- A For a lot of hematological malignancies, HPCT following myeloablative or reducedintensity conditioning (RIC) still is the only curative therapeutic option. Bone marrow (BM) or mobilized peripheral blood stem cells (PBSC) from a matched sibling donor (MSD) are the first choices in HPCT. Unfortunately, not for every patient, a MSD is available and thus, alternative sources of HPC come into play: BM or PBSC from a matched unrelated donor (MUD) or a partially mismatched related donor (haploidentical) and umbilical cord blood (UCB). B This section highlights the indication for adoptive cell therapy (ACT) and donor lymphocyte infusion (DLI). In case of RIC, a T-cell depleted transplant or mixed chimerism, ACT/DLI are prophylactically given to the patient. Therapeutically applicated ACT/DLI are indicated in case of minimal residual disease (MRD), leukemic relapse or infectious complications like cytomegalovirus (CMV), Epstein-Barr-Virus (EBV) infection or invasive aspergillosis (IA). C On the one hand, DLI brings the graft-versus-leukemia effect (GvL) and on the other hand it causes graft-versus-host-disease (GvHD). The challenge is to manipulate DLI or use specific cell populations to enhance GvL (GvL ) while reducing GvHD (GvHD ). New strategies to achieve these two aims are currently developed: Lymphocytes are genetically engineered, e.g., with the herpes-simplex-virus thymidin-kinase (HSV-TK), antigen-specific lymphocytes are selected by streptamer isolation (Streptamer), Tregs, NK cells and T helper (Th) cells as well as T cells engineered to express antigen-specific T-cell receptors (TCR) or 'T bodies' are used. Another approach is the application of T cells parallel to a vaccine, so-called vaccine-enhanced (VE) T cells. served after allogeneic HPCT and DLI is based on the CTLmediated immunity which is reactive against minor histocompatibility antigens (mHAgs) as well as tumor/leukemia-associated antigens (TAA/LAAs) [25] [26] [27] . Minimal residual disease markers like BCR-ABL in chronic myelogenous leukemia (CML), and the proposed marker JAK2 in BCR-ABL-negative myeloproliferative neoplasms, are negative in patients in complete remission -underlining the role of T-cell-mediated immunity in the treatment [28, 29] . These immunological effects demonstrate the potential of donor lymphocytes to reject malignant cells and suggest that LAAs are recognized by these donor lymphocytes.
Reduced Intensity Conditioning and Prophylactic Donor Lymphocyte Infusion
However, during the past decade several aspects in the conditioning regimen changed to pave the way for application of HPCT to a broader range of patients. RIC was introduced with a consequentially reduced toxicity, but GvHD-associated morbidity and mortality remained [30] . Efforts have been made to reduce GvHD-associated morbidity and mortality by in vivo T-cell depletion but this happened on the expense of impaired immune reconstitution which implicates an increased incidence of opportunistic infections and a reduced GvL effect [33, 34] . A retrospective study of the International Bone Marrow Transplant Registry (IBMTR), described an increased leukemia relapse rate when the stem cell transplant was T-cell depleted, underlying the importance of T cells as effector cells in GvL [31] . Subsequently, prophylactic and dose-escalated DLI was integrated in RIC protocols to reinforce the GvL effect and prevent disease relapse but the risk of inducing GvHD remains [32] .
Up to now, HPCT remains a balancing act between GvL and GvHD. Therefore, new strategies to improve early immune reconstitution and to potentiate GvL without reinforcing GvHD are needed. The following sections are going to describe the use of adoptive immunotherapy as an instrument to achieve these two aims.
Adoptive T-Cell Transfer in Viral Reactivation and Fungal Infection
After HPCT the phase of immune reconstitution represents the vulnerable phase for viral and fungal infections. Reactivation of latent viruses like cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV) and varicella zoster virus (VZV) is frequent in this period and leads to a symptomatic disease in many cases. For example, up to 80% of CMV-seropositive allogeneic HPCT recipients develop CMV reactivation, 50% with viremia, and 40% develop active disease with pneumonia, gastroenteritis, hepatitis or retinitis [16, 37] . The antiviral drugs available are ganciclovir, foscarnet or cidofovir; however, the setback is [11] . If there is no matched donor available, haploidentical and umbilical cord blood (UCB) transplantation come into play. A great advantage of a haploidentical transplant is that the donor is immediately available even for a second graft in the case of graft rejection. But due to HLA differences the risk of developing fatal GvHD is very high. To overcome this risk, there are several strategies to reduce the T-cell load in the graft. One possibility is an intensified conditioning regimen with fludarabin, thiotepa and total body irradiation, followed by infusion of G-CSF-stimulated peripheral blood CD34+ selected cells and combined with in vivo T-cell depletion using ATG [12, 13] . An alternative is CD3+/CD19+ cell depletion within G-CSF-mobilized peripheral blood cells to gain a graft with large numbers of CD34+ cells, CD34-cells, CD8+ cells and NK cells [15] . This protocol is combined with RIC and subsequent immunosuppression. The main problem of these regimen is the delayed T-cell reconstitution with consecutive serious infectious problems such as CMV reactivation or invasive aspergillosis [14, 15] .
UCB collected from the umbilical cord and placenta of a healthy newborn is another source if no matched related or unrelated donor is available. Due to the cell number needed for adults, a single UCB unit is not sufficient. Thus, the use of a transplantation of usually two UCB units [16] as well as in vitro expansion of CD34+ cells from UCB are under investigation [17] . Interestingly, GvHD in patients with UCB transplantation is decreased, and relapse rates are comparable to peripheral blood stem cell or bone marrow transplantation [18] . But infections are more frequent and more severe in the early posttransplant phase by day 100 after UCB transplantation [19] . This fact originates in the cell features of UCB cells: UCB T cells are naive and not antigen-experienced, show less proliferation and INF-production in response to cognate antigens and have deficits in signal transduction mechanisms [20] . A further observation is that Tregs from UCB have more potent suppressor functions than adult Tregs [23] . Due to its cell characteristics, UCB is not only a source for HPCT but also a cell source for Tregs and NK cells [21] for ACT.
The Role of Donor Lymphocyte Infusion in Allogeneic Hematopoietic Progenitor Cell Transplantation
Infusion of donor lymphocytes (DLI) several weeks after HPCT (also called 'delayed' DLI) already plays a key role in supporting the graft-versus-tumor effect after allogeneic HPCT although the potency of DLI differs for each disease entitiy [22] [23] [24] . The graft-versus-leukemia (GvL) effect ob-Specific Antigen-Specific T Cells Another concept to avoid GvHD is isolating specific CTLs by several multimer techniques -using tetramers, pentamers [46] or streptamers [47] . CMV-specific CTLs isolated by streptamer technology are shown to have a preserved function. Currently a clinical phase I/II trial is ongoing, testing the adoptive immunotherapy of chemorefractory CMV infections with streptamer-selected T cells after HPCT. Schmitt et al. [48] reported about 2 patients in whom adoptive transfer of streptamer-selected CMV-specific CTLs lead to virus clearance after allogeneic HPCT.
It is described that long-standing responses to viral infections depend on the presence of Th cells to help CTLs [49] . Feuchtinger et al. [50] reported about the isolation of antigenspecific CD4+ and CD8+ T cells from blood of CMV seropositive donors based on the pp65-specific IFN-secretion of T cells after ex vivo stimulation with the viral antigen. This method proved to be safe, feasible and effective as a treatment on demand for refractory CMV infection post HPCT.
Regulatory T Cells CD4+ CD25+ Tregs, another population of interest in preventing GvHD, are central actors in maintaining self-tolerance and circumventing autoimmunity [51] . Technically, Treg separation with the help of antibody-coated magnetic beads followed by ex vivo expansion is a time-consuming and costly challenge and has to follow GMP standards to be evaluated in clinical trials. But there is a lot of promising data focusing on this cell population. Taylor et al. [52] first demonstrated in the mouse model that depletion of CD4+ CD25+ T cells from the donor T-cell population or in vivo CD25+ depletion of the recipient resulted in increased GvHD which could be ameliorated by infusion of ex vivo activated and expanded donor CD4+ CD25+ cells [52] . Freshly isolated Tregs were also able to partially suppress GvHD [52] [53] [54] with the limitation that they are only found in a low frequency in peripheral blood and there is a large number needed for suppressing GvHD. Therefore ex vivo expansion seems to be needed. Interestingly, with transfer of Tregs, GvL was preserved while GvHD was suppressed [55, 56] . Importantly, Tregs should be administered early after HPCT because there are no data about reversing well-established GvHD [57] . Godfrey et al. [58] used UCB as the source for Tregs because in UCB there is a lack of memory T cells. Tregs were isolated by magnetic cell sorting, activated with anti-CD3/CD28 beads and then cultivated with IL-2. Those cells were able to suppress more than 95% of allogeneic mixed lymphocyte reactions (29 of 30 donors) [58] . Some clinical trials are underway to examine the adoptive transfer of donor Tregs to prevent GvHD. The side effects and the optimal dose of donor Tregs are tested in an ongoing phase I clinical trial called 'T-Regulatory Cell Infusion post Umbilical Cord Blood Transplant in Patients with Advanced Hematologic Cancer' (ClinicalTrials.gov Identifier: NCT00602693). In another phase I trial, headed by M. Edthat they are costly and potentially cause severe side effects and that some patients even show a chemorefractory viral disease [33] . Therefore, other strategies are needed to accelerate immune reconstitution. Non-manipulated DLI may contain virus-specific T cells acting against latent viruses such as CMV with average values of 0.75% and 1.85% for HLA*A0201-and HLA*B702-restricted pp65 peptides with a range from 0.13% up to 5% from all CD8+ T cells [34] . The frequency of EBV-specific CTLs in healthy virus carriers is about 1-5% from all CTLs [35] . Several groups could demonstrate a clinically relevant reconstitution of the immune system [36, 37] .
Analogously to viral infections and despite prophylactic and preemptive antifungal therapy, a further major cause of morbidity and mortality of patients after HPCT is invasive aspergillosis caused by Aspergillus fumigatus [15] . Similarly to viral reactivation, invasive aspergillosis occurs in the phase of immune reconstitution; interestingly, it was reported that patients surviving aspergillosis showed significant antigenspecific proliferation of INF-producing Th cells [38] .
However, non-manipulated DLI contains a serious number of alloreactive T cells which was related to a significantly increased risk of GvHD. To provide early immune reconstitution and to reduce the risk of GvHD, CTLs specific for viral antigens such as EBV or CMV are successfully transferred to patients with active viral disease [37, 39, 40] . Not only for treatment but also for prophylaxis of EBV-associated posttransplant lymphoproliferative disease, donor-derived polyclonal EBV-specific T-cell lines were successfully applied to the patients [40, 41] . Recently, a method for rapid clinicalscale generation of human anti-Aspergillus-specific T cells was developed [42] .
Controlling Graft-versus-Host Disease
Suicide Gene Transfected Donor T Cells One approach to minimize the risk of GvHD induced by DLI is the transfection of T cells with a so-called suicide gene. In patients with GvHD, this gene can be activated by the administration of a drug, and as a result the transfected T cells are eliminated. The suicide gene most commonly applied is the thymidine kinase of herpes simplex virus (HSV-TK) which is sensitive to ganciclovir. In addition, the infusion of those genetically engineered donor lymphocytes promotes early immune reconstitution [43, 44] . One limitation of this method is that transferred cells are eliminated if early viral infection prior to HSV-TK T-cell engraftment takes place and therapy with ganciclovir is needed. Another problem is that HSV-TK represents a foreign antigen, and the transfected cells will be eliminated consequently through CTLs recognizing this particular antigen. Therefore, a second generation of suicide genes like inducible caspase 9 has been developed for adoptive T-cell therapies [45] . do not express those alleles. Alloreactive NK cells are able to kill host-type dendritic cells (DCs) which present host alloantigens to donor T cells; thus T-cell mediated GvHD is prevented [68, 69] . Consequently, the infusion of donor NK cells, alloreactive against the recipient, blocked T-cell-mediated GvHD. The extent was so strong that mice given alloreactive NK cells as part of the conditioning regimen showed no clinical or histological evidence of GvHD even after receiving mismatched bone marrow grafts containing up to 30 times the lethal dose of T cells. Alloreactive NK cells were able to kill malignant cells in acute myelogenous leukemia (AML), CML, acute lymphoblastic leukemia (ALL), T-cell acute lymphoblastic leukemia (T-ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL) and multiple myeloma, but not in common ALL [70, 71] . Resistance was associated with lack of leukocyte function-associated antigen-1 (LFA-1) expression. In a preclinical model, transfer of alloreactive NK cells into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice showed no clinical or histological evidence of GvHD, and mice eradicated transplanted human AML [68] . The role of NK cells in mismatched unrelated HPCT is not so clear, but recent studies show a delayed and poor reconstitution of NK cells due to the high amount of immunosuppressive drugs in this context [72] . Interestingly NK cells can be used in different settings. A study in relapsing AML patients demonstrated that NK cells harvested from haploidentical donors and infused after lymphoablating chemotherapy in the non-HPCT setting is safe and transient in vivo expansion could be detected [73] . The NKAML pilot trial [74] demonstrated the feasibility and safety of immunosuppresion with cyclophosphamide and fludarabine, followed by the infusion of donor-recipient inhibitory KIR-HLA-mismatched NK cells in 10 patients with AML as a consolidation therapy after completed chemotherapy. Contamination with B or T cells was minimal in this study and engraftment was detected in all patients. All patients remained in complete remission after a follow-up of approximately 32 months [74] . Another possibility shown by several groups is blocking the NK cell inhibitory receptors in the autologous setting. This strategy is currently tested in a phase I clinical trial with a fully human monoclonal antibody (1-7F9) in elderly patients with AML [75] . This antibody recognizes KIR2D inhibitory receptors and blocks the interaction with HLA-C molecules leading to NK cell-mediated lysis of leukemic cells. Interestingly, self-tolerance, NK cell education and function were not interfered and NK cell killing with consecutive tumor eradication was shown in preclinical murine models [76, 77] . Another possible mechanism triggered by NK cells is a polarization of the Th response towards Th2 cells [78] .
The Potential Role of CD4+ Th Cells
A wide field in tumor immunology concentrates on tumorspecific CTLs which are able to directly lyse tumor cells. But inger, patients with high disease relapse risk or minimal residual disease after HPCT who would preemptively receive DLI after cessation of immunosuppressive GvHD prophylaxis are sequentially treated with non-manipulated Tregs (between 1 × 10 6 and 5 × 10 6 cells/kg body weight) that are freshly isolated from the original stem cell donor. Conventional DLI with equal T-cell numbers followed the infusion of Tregs. Ex vivo expansion is avoided in this protocol. Preliminary data demonstrated safety; no acute toxicities or complications like disease relapse, GvHD or infections were reported [59] . Nevertheless, Treg therapy might carry the risk of immunosuppression and consecutive disease relapse or tumor reoccurrence. In protocols with ex vivo expansion regimens, uncontrolled cell proliferation and eventually loss of the suppressor function of Tregs could be the result. It remains to be demonstrated whether those concerns are reasonable or not.
Enhancing Graft-versus-Leukemia Effect

Engineered T Cells
An alternative approach focuses on the selectivity of the donor cells. T cells can be engineered to express T-cell receptors (TCRs) which selectively recognize TAAs/LAAs. Xue et al. [60] demonstrated in an in vivo model that T cells, engineered to express the WT-1-TCR, are able to eliminate autologous leukemia progenitor cells [60] . Again, this strategy has limitations because every TCR recognizes the antigen in a MHC-restricted manner. Therefore, it can only be used in patients with the required MHC allele [61] . To circumvent this restriction, T cells which express novel chimeric fusion proteins that link the antigen-binding domain of the B-cell receptor with the signaling component of the TCR complex -socalled 'T bodies' -are used. To date there are only data using these TCRs for solid tumors [62] . Another restriction is that the cultured T cells used for ACT have a limited replicative potential. To improve the situation, enforced expression of co-stimulatory molecules as well as telomerase have been used [63, 64] .
NK Cells
In haploidentical HPCT, NK cell alloreactivity is a crucial therapeutic mechanism. For NK cell function, inhibitory as well as activating killer immunoglobulin-like receptors (KIRs) are of importance. NK cells are regulated by MHC I on target cells, they are inhibited in their function by self-MHC I molecules [65] . Autologous cells are not killed by NK cells as NK cells express receptors for self-MHC I molecules, so-called inhibitory KIRs [66, 67] .
In the setting of mismatched allogeneic HPCT, NK cells are not stopped from killing due to a missing expression of self-MHC I molecules -the missing self recognition mechanism. The KIRs recognize specific HLA-C allele groups and/ or the HLABw4 group and are alloreactive against cells who cytokines IL-2, IL-12 and INF-upon alloantigen stimulation were reported [86] [87] [88] . However, in a recent study, Hill et al. [89] postulated that G-CSF rather invokes Th17 induction than Th1 or Th2 differentiation [89] . To summarize, a lot of data indicates that G-CSF promotes an immune tolerant state in T cells by inducing a shift towards Th2 and even Tregs [90] , apart from the pro-inflammatory subset Th1 while the effect of G-CSF on Th17 cells is controversially discussed.
Vaccine-Enhanced T Cells
A novel approach to improve immune function and link the two aims -enhancing GvL and suppressing GvHD -following HPCT, is vaccination-enhanced DLI which serves as an in vivo expansion of specific T cells [91] . A key advantage of this method would be that no labor-or cost-intensive in vitro expansion of specific T cells would be needed and at the same time two clinically approved techniques could be combined: DLI plus vaccination (peptides, DCs). This concept was tested recently by Levenga et al. [92] in patients with multiple myeloma receiving a combination of DLI and DC vaccination after HPCT [92] . Analogously, it could become a concept to treat patients with CMV reactivation after HPCT to combine CMV-peptide vaccination with DLI [93] .
Leukemia-Associated Antigens as Target Structures for T-Cell Therapy after HPCT
To improve the effects of immunotherapy, it is important to develop more leukemia-specific T-cell therapies. The antitumor effect of an adoptive T-cell immunotherapy critically depends on the selection of the target antigen. First, the ideal antigen would be highly immunogenic to elicit a specific T-cell response. Second, it would be selectively expressed by leukemic cells and ideally not by normal tissue, thus preventing GvHD. Third, it should be expressed or at least be presented on the surface of the cells. Fourth, it should play a key role in proliferation and survival of the leukemic cells so that targeting the antigen would lead to apoptosis of the malignant cells.
On the one hand, mHags such as HA-1, HA-2, PANE-1 and LRH-1 are suitable antigens [94] [95] [96] . A clinical phase I study previously tested the CTL transfer specific for mHags with the potential risk of inducing severe GvHD [97] . This study underlines the importance of selecting the ideal tissuerestricted antigen.
On the other hand, LAAs are defined, and candidates like WT1, PR3, hTERT, Survivin, PRAME and RHAMM are available [98] . The frequency of LAA-specific CTLs is often very low. Hence, efforts are made to expand LAA-specific T cells in vitro for ACT in vivo with the help of peptide vaccination. For example, Quintarelli et al. [99] generated HLA-A02-restricted PRAME-specific CTL responses, demonstrating the possible role of this LAA for peptide vaccination by means of in vivo expansion of CTLs in CML. Interestingly, with growing knowledge, Th cells are becoming increasingly important in their role in orchestrating an antitumor response. Th cells are providing additional stimuli to CTLs [79] . Furthermore, Th cells have the advantageous ability to recognize antigens that are presented by HLA-II molecules. These HLA-II molecules are only expressed on antigen-presenting cells, and these cells in turn close the gap between Th and CTL co-stimulation. Interestingly, HLA-II molecules can be up-regulated in tumor cells with the help of INF-; then they have a cytotoxic effect themselves [80] . But the experience with Th cells in adoptive cell therapy is very limited. It is more difficult to expand those cells in vitro, and due to the different Th subgroups (Th1, Th2, Th17, Treg) their phenotype is dramatically influenced by culture conditions [81] . Kim et al. [82] tested the potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for a sustained remission of refractory AML. A case of a 48-year-old man with myelodysplastic syndrome (RAEB-2) that progressed to AML shortly after primary diagnosis was reported. After HPCT from an HLA-matched sibling and after conditioning with fludarabine and busulfan, no GvHD occurred, but relapse appeared 10 months post transplantation. As salvage chemotherapy (FLAGIda) and repeated DLI with stem cell support resulted in complete remission of the AML and leukemic blasts showed WT1 expression, an immunotherapy with allogeneic WT1-CTLs was performed. WT1-CTLs were generated in vitro by co-cultivation of immature DCs infected with recombinant adenovirus encoding truncated WT1 and donor lymphocytes. The proportion of CD4+ and CD8+ cells was 30% and 66%, respectively. Four doses of WT1-CTLs were administered after DLI and CD34 cell therapy, and the patient remained free of leukemia for 37 months after immunotherapy until relapse [82] . In conclusion, in orchestrating a sufficient antitumor immune response, Th cells seem to play a key role. Thus, the concept of successful adoptive immunotherapy would be a combination of antigen-specific Th cells with CTL cells.
To date, the majority of stem cell transplants for hematopoietic transplantation is mobilized by G-CSF, which means a 10 times increased number of T cells infused compared to an equivalent bone marrow graft. In a meta-analysis, a decreased relapse rate and an increased GvL effect was reported for patients with early-and advanced-stage disease as well as a significant risk for the development of chronic GvHD [83] . Interestingly, acute GvHD is described as a Th1 (secreting IL-2 and INF-)-mediated disease with induction of a cytokine storm, whereas chronic GvHD seems to equal in part an autoimmune disease [84, 85] . Th2 cells (secreting IL-4 and IL-10) seem to suppress inflammatory processes and reduce acute GvHD. The risk of acute GvHD decreases possibly due to the immunomodulatory effect of G-CSF shown by several groups. G-CSF mobilization leads to a polarization of Th cells towards the Th2 cell pool, therefore elevated levels of type 2 cytokines (IL-4 and IL-10) and decreased levels of the type 1 Nevertheless, the future of ACT may lie in combining several strategies like pretreatment with lymphodepleting chemotherapy and adoptive T-cell transplantation with vaccination to increase the tumor-reactive T-cell population in vivo. 
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The application of some LAAs after HPCT is tested in various studies. A phase I trial with the bivalent peptide vaccination of PR1 and WT1 demonstrated immunological but also clinical responses of patients after allogeneic HPCT [100] . A phase I/II trial for patients with AML, myelodysplastic syndrome and multiple myeloma was performed for RHAMMlikewise with the detection of clinical and immunological responses [101, 102] .
For the future, the combination of peptide or DC vaccination with DLI (vaccine-enhanced DLI) would be a promising concept to enhance GvL and suppress GvHD but further studies have to confirm their relevance in vivo.
Conclusion
To date, HPCT is a promising treatment option in several hematological malignancies. However, delayed immune reconstitution with viral reactivation, development of GvHD and disease relapse still represent risks that cannot be sufficiently controlled in every patient. Therefore, the ambitious aim of adoptive immunotherapy is to enhance GvL and im-
